

# MARKET ANNOUNCEMENT

---

## USA FDA clearance for Thor ultrasonic spirometers

**Sydney, Australia: Wednesday, 29<sup>th</sup> July 2015:** Uscom (ASX code: UCM) (the **Company** or **Uscom**), a revenue stage, cardiovascular medical technology company, is pleased to confirm the USA Food and Drug Administration (FDA) recognised the SpiroThor digital ultrasonic spirometers as equivalent to predicated class II diagnostic spirometers and therefore approved the devices for marketing into the USA.

Uscom has entered into an agreement to purchase 100% of Thor operations and intellectual property, subject to completion of satisfactory due diligence.

Thor Laboratories manufacture a range of high accuracy digital ultrasonic spirometers for the specialized for measurement and monitoring of lung function and lung therapy, with particular application in asthma and chronic obstructive pulmonary disease (COPD), and emerging applications in sleep medicine.

Thor is a cash flow positive medical device manufacturer with current annual revenues of approximately \$500k AUD. Its devices already have CE and TGA approvals. Uscom management considers the Thor acquisition to be a key strategic growth opportunity, providing additional revenue, internationally accredited manufacturing and R&D capabilities, distribution and a product suite of ultrasonic spirometers for Uscom to feed into its growing global distribution network.

Uscom CEO, Associate Professor Rob Phillips said, *"Products are profit, and the FDA approval of the Thor ultrasonic spirometers provides great commercial opportunity for Uscom to expand into the US market. One person dies from COPD every 4 minutes in the US and asthma continues to increase world wide as air quality deteriorates. There are a number of different technologies applied to spirometry, but digital Doppler ultrasound is considered the most accurate, and the Thor products are class leading. These spirometers are complimentary to the USCOM 1A cardiac output and Uscom BP+ central blood pressure monitors, which already have FDA approval. Our philosophy has been to develop and market the best quality non-invasive technologies in vital clinical applications. This acquisition and FDA approval, now allows us to deliver practice leading devices into the lucrative US cardiac, vascular and pulmonary markets."*

*Our newly appointed US VP of Business Development, Stephen Wilson, spent 10 years marketing blood pressure technologies and spirometers for Welch Allyn, and is well qualified to ensure the Thor devices are effectively delivered into the substantial US markets."*

Uscom recently raised \$1.55m via a placement of shares to new and established institutional and sophisticated investors, with a further \$0.4m underwritten for sale to existing shareholders via an SPP in the coming weeks. These funds will be used for the Thor acquisition and for working capital.



**Uscom Limited**

ABN 35 091 028 090

Suite 1, Level 7, 10 Loftus Street

Sydney NSW 2000 Australia

T +612 9247 4144 F +612 9247 8157

[www.uscom.com.au](http://www.uscom.com.au)

# MARKET ANNOUNCEMENT

---

## About Uscom

Uscom Limited (UCM) is an ASX listed cardiovascular medical device company. Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the Uscom BP+. Both devices are clinically validated with FDA, CE and TGA regulatory registration, and are currently being marketed into global distribution networks.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects circulatory abnormalities and guides treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, heart failure, and for the guidance of fluid therapy.

The Uscom BP+ is a supra systolic Central Blood Pressure monitor and replaces older and more widespread sub systolic Blood Pressure monitoring technology. Central Blood Pressure is emerging as the new standard of care in hypertension and heart failure. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and arterial pulse pressure waveforms, measures otherwise only available by cardiac catheterisation. The Uscom BP+ is simple to use and measures from a familiar upper arm cuff, and requires no complex training, and has applications in cardiology, intensive care, general practice and home care.

For more information, please visit: [www.uscom.com.au](http://www.uscom.com.au)

## Uscom Contacts

Assoc. Professor Rob Phillips  
Executive Chairman  
[rob@uscom.com.au](mailto:rob@uscom.com.au)

Catherine Officer  
Company Secretary  
[secretary@uscom.com.au](mailto:secretary@uscom.com.au)